View All Conferences
60th ASH Annual Meeting & Exposition
Mohamad Mohty, MD, PhD, Discusses Cytotoxic T Lymphocytes as Potential EBVPTLD Therapy
Mohamad Mohty, MD, PhD, discusses the investigational therapy cytotoxic T lymphocytes (CTLs) therapy for the treatment of Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBVPTLD).
Peter Turecek, PhD, Explains How Medical Devices May Benefit Patients with Hemophilia
An early prophylaxis in combination with an assistant device like myPKFit can improve the outcomes of treatment.
Ruxolitinib Therapy Benefits Patients with Chronic Neutrophilic Leukemia
This rare leukemia form may be treated with ruxolitinib, which appears to be well-tolerated by patients.
Hydroxyurea Therapy Found Effective for Myeloproliferative Neoplasms
Patients with myeloproliferative neoplasms (MPN) with essential thrombocythemia (ET) or polycythemia vera (PV) were found to benefit from hydroxyurea therapy.
Pemigatinib Shows Promising Efficacy as Myeloid/Lymphoid Neoplasms Treatment
Patients with myeloid/lymphoid neoplasms enrolled in the phase 2 clinical trial demonstrated pemigatinib was generally well-tolerated.
Nizar Bahlis, MD, Recaps Follow-Up Data on Combo Therapy for R/R Multiple Myeloma
Nizar Bahlis, MD, highlights the phase 3 POLLUX trial evaluating daratumumab plus lenalidomide and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma.
Potential Paroxysmal Nocturnal Hemoglobinuria Treatment, APL-2, Shows Positive Trial Update
Among the highlights, significant and sustained increases in hemoglobin without transfusions stood out.
John Leonard, MD, Reviews Investigational R/R Follicular Lymphoma Treatment
Lead investigator, John Leonard, MD, reviews the phase 3 AUGMENT trial investigating lenalidomide plus rituximab for the treatment of relapsed/refractory follicular lymphoma.
Patients with Sickle Cell Disease Benefit Most from Interventions That Reduce Hemolytic Anemia
Models show that for every gram of hemoglobin increased per deciliter, the risks associated with hemolytic anemia decrease.
Jorge Cortes, MD, Reviews Positive Phase 3 Quizartinib Data for AML Treatment
Jorge Cortes, MD, highlights the phase 3 QuANTUM-R trial results and explains their clinical implications for patients with
-ITD-mutated relapsed/refractory acute myeloid leukemia (AML).
Next Page >>
MOST POPULAR ARTICLES
ADA-SCID (aka Bubble Baby Disease) Cured by Gene Therapy
FDA Approves IND Application for Traumakine
Clementia Announces Phase 2 Trial Fibrodysplasia Ossificans Progressiva Treatment Results
Failure of Polycythemia Vera Control with Phlebotomy
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2019 Rare Disease Communications. All Rights Reserved.